Cyber Monday saleUp to 70% OFF
888

GENETIC ANALYSIS NK -,60

No trades
See on Supercharts
Overview
Financials Discussions Seasonals

8V8 chart


Full chart

8V8 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.25 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.0418 EUR
Net income (FY)
‪−2.12 M‬ EUR
Revenue (FY)
‪1.26 M‬ EUR
Shares float
—
Beta (1Y)
0.09

About GENETIC ANALYSIS NK -,60


Sector
Health Technology
Industry
Medical Specialties
CEO
Ronny Hermansen
Website
genetic-analysis.com
Headquarters
Oslo
Founded
2008
ISIN
NO0010692130
FIGI
BBG0136X5Q37
Genetic Analysis AS develops in-vitro diagnostics tests in diseases where microbiota is involved. It is a molecular diagnostic company that provides gut microbiota analysis for testing bacterial imbalance in bowel syndrome and inflammatory bowel disease patients. The company's service products include GA-map dysbiosis test and COVID-19 fecal test and lab products include The GA-map dysbiosis test reagent kit and The COVID fecal test reagent kit. Genetic Analysis was founded in 2008 and is headquartered in Oslo, Norway.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange GENETIC ANALYSIS NK -,60 stocks are traded under the ticker 8V8.
8V8 reached its all-time high on Nov 5, 2021 with the price of 0.9780 EUR, and its all-time low was 0.0100 EUR and was reached on Oct 28, 2021. View more price dynamics on 8V8 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track GENETIC ANALYSIS NK -,60 financials in yearly and quarterly reports right on TradingView.
GENETIC ANALYSIS NK -,60 is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
8V8 net income for the last quarter is ‪−274.13 K‬ EUR, while the quarter before that showed ‪−420.14 K‬ EUR of net income which accounts for 34.75% change. Track more GENETIC ANALYSIS NK -,60 financial stats to get the full picture.
No, 8V8 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENETIC ANALYSIS NK -,60 EBITDA is ‪−1.78 M‬ EUR, and current EBITDA margin is −217.41%. See more stats in GENETIC ANALYSIS NK -,60 financial statements.
Like other stocks, 8V8 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENETIC ANALYSIS NK -,60 stock right from TradingView charts — choose your broker and connect to your account.